Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$89.13 ▲ +1.14
(+1.30%)
MKT CAP: $22.39B • VOL: 692.7K
52W L $80 52W H $124
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$75
MEDIAN
$100
MEAN
$102
HIGH
$121
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BNTX TAPE
BNTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $107.85 | $102.50 | 2025-02-14 | $81.11 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $112.30 | $105.17 | 2025-02-06 | $83.78 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $101.61 | $98.04 | 2025-01-29 | $85.56 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $90.91 | — | 2025-01-17 | $87.35 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $78.43 | $84.67 | 2025-01-09 | $79.33 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $106.06 | $92.70 | 2024-12-18 | $77.54 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $86.46 | $90.02 | 2024-12-04 | $82.89 | -4.3% | 48% | C |